Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases

Am J Hematol. 2020 May;95(5):E117-E120. doi: 10.1002/ajh.25751. Epub 2020 Feb 17.

Authors

Luis E Malpica Castillo¹, Shannon Palmer², Anqi Zhu³, Allison M Deal³, Sheh-Li Chen², Stephan Moll¹

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
² Department of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.
³ Biostatistics Shared Resource, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.

PMID: 32017201
DOI: 10.1002/ajh.25751

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Female
Hematologic Diseases
Humans
Incidence
Male
Middle Aged
Neutropenia / chemically induced*
Retrospective Studies
Rituximab / adverse effects*

Substances

Antineoplastic Agents, Immunological
Rituximab